- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Study supports use of amoxicillin-clavulanate for diverticulitis
Treating diverticulitis in the outpatient setting with the antibiotic combination amoxicillin-clavulanate may reduce the risk for fluoroquinolone-related harms without adversely affecting diverticulitis-specific outcomes. As such, physicians may want to consider choosing amoxicillin-clavulanate over metronidazole-with-fluoroquinolone for patients with a first occurrence of diverticulitis. Findings from two nationwide cohort studies are published in Annals of Internal Medicine.
Researchers from the University of North Carolina at Chapel Hill have found no differences in the 1-year risk of hospital admission or urgent surgery, or the long-term risk of elective surgery. Furthermore, older patients treated with metronidazole-with-fluoroquinolone had an increased risk of Clostridioides difficile infection (CDI).
Uncomplicated diverticulitis is often managed in the outpatient setting with antibiotics to expedite recovery from the acute episode and reduce the risk for obstruction, abscess, or perforation. The two most commonly prescribed antibiotic regimens for this purpose are a combination of metronidazole and a fluoroquinolone or amoxicillin-clavulanate only. Despite being commonly prescribed for diverticulitis, the effectiveness and harms of these antibiotics remain unknown. This is a critical gap because the U.S. Food and Drug Administration has recommended that fluoroquinolones be reserved for use in conditions with no alternative treatment options because of the risk for potentially permanent and disabling fluoroquinolone-related adverse effects.
Researchers from the University of North Carolina School of Medicine studied two nationwide claims databases to compare the effectiveness of treating patients at the first occurrence of outpatient diverticulitis with either a combination of metronidazole and a fluoroquinolone or amoxicillin-clavulanate alone for the prevention of diverticulitis-related inpatient admission, urgent surgery, elective surgery, and emergency department visits. In addition, the researchers sought to assess the comparative risk for Clostridioides difficile infection (CDI) associated with these treatments. They found that amoxicillin-clavulanate was as effective as treatment with metronidazole-with-fluoroquinolone and there were negligible differences between groups in risk for the adverse outcomes measured. According to the researchers, these findings suggest that physicians may want to consider choosing amoxicillin-clavulanate over metronidazole-with-fluoroquinolone to reduce the risk for serious harms associated with fluoroquinolone use, including CDI.
Hina Zahid Joined Medical Dialogue in 2017 with a passion to work as a Reporter. She coordinates with various national and international journals and association and covers all the stories related to Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in the medical field. Email:Â editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751